Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Investors in Iovance Biotherapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed operational issues affecting the company's performance [1]. Group 1: Lawsuit Details - The lawsuit alleges that from May 9, 2024, to May 8, 2025, the defendants failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to start treating patients with Amtagvi [2]. - It is claimed that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-off rates [2]. - These operational challenges led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, contradicting the defendants' positive statements about the company's business and prospects [2].